Andrew Morin

Title: Andrew Morin: Innovator in Engineered Polypeptides

Introduction

Andrew Morin is a notable inventor based in San Mateo, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of engineered polypeptides. His work focuses on innovative solutions that enhance the selection and application of binding molecules.

Latest Patents

Andrew Morin holds a patent for "Engineered CD25 polypeptides and uses thereof." This patent provides engineered polypeptides that incorporate a combination of spatially-associated topological constraints, with at least one constraint derived from a CD25 reference target. The patent also outlines methods for selecting these engineered polypeptides and their applications, including their use as positive and/or negative selection molecules in screening libraries of binding molecules such as antibodies. Additionally, the patent details the selection of CD25 antibodies using these engineered polypeptides.

Career Highlights

Andrew Morin is currently associated with Ibio Limited, where he continues to advance his research and development efforts. His innovative approach to biotechnology has positioned him as a key player in the field.

Collaborations

Andrew has collaborated with notable colleagues, including Matthew Paul Greving and Phung Tu Gip. These partnerships have further enriched his research and contributed to the success of his projects.

Conclusion

Andrew Morin's work in engineered polypeptides exemplifies the innovative spirit of modern biotechnology. His contributions are paving the way for advancements in the selection and application of binding molecules, showcasing the importance of his research in the scientific community.